Patents by Inventor Kwang Nho

Kwang Nho has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030153694
    Abstract: Novel monofunctional polyethylene glycol aldehyde for pegylating therapeutically active proteins to produce pegylated protein conjugates which retain a substantial portion of their therapeutic activity and are less immunogenic than the protein from which the conjugate is derived and a new synthesis for preparing such aldehydes.
    Type: Application
    Filed: November 25, 2002
    Publication date: August 14, 2003
    Inventors: Perry Rosen, Kwang Nho
  • Patent number: 5658879
    Abstract: The use of hemoglobin-polymer conjugates to enhance antitumor therapy in mammals is disclosed. The methods include administering an effective amount of an antitumor therapy such as radiation in combination with hemoglobin conjugated to a substantially non-antigenic polymer.
    Type: Grant
    Filed: October 16, 1995
    Date of Patent: August 19, 1997
    Assignee: Enzon, Inc.
    Inventor: Kwang Nho
  • Patent number: 5478806
    Abstract: The use of hemoglobin-polymer conjugates to enhance antitumor therapy in mammals is disclosed. The methods include administering an effective amount of an antitumor therapy such as radiation in combination with hemoglobin conjugated to a substantially non-antigenic polymer.
    Type: Grant
    Filed: March 16, 1994
    Date of Patent: December 26, 1995
    Assignee: Enzon, Inc.
    Inventor: Kwang Nho
  • Patent number: 5478805
    Abstract: Hemoglobin-containing solutions containing polyalkyene oxide-conjugated hemoglobin having a molecular weight greater than about 85,000 daltons and a degree of substitution of at least five polyalkylene oxide conjugates per hemoglobin molecule are described that are not associated with hemoglobinuria in mammals. A method of simultaneously fractionating and purifying polyalkylene oxide-conjugated hemoglobins is also disclosed.
    Type: Grant
    Filed: November 3, 1993
    Date of Patent: December 26, 1995
    Assignee: Enzon, Inc.
    Inventors: Robert G. L. Shorr, Myung-Ok P. Cho, Kwang Nho
  • Patent number: 5386014
    Abstract: The present invention relates to chemically modified hemoglobin produced by a novel and efficient method in which stroma-free hemoglobin is first effectively deoxygenated and reduced and then conjugated with a polyalkylene oxide such as polyethylene glycol (PEG) under conditions which maintain the structural integrity of the heme oxygen binding site. In specific, preferred embodiments of the invention, the deoxygenation and reduction is performed under an inert atmosphere by the amino acid cysteine. In additional specific, preferred embodiments, the structural integrity of the heme oxygen binding site is maintained by a high anionic concentration in the reaction mixture. In further preferred specific emodiments of the invention, the polyalkylene oxide is polyethylene glycol; in still further preferred specific embodiments of the invention, the polyalkylene oxide is linked to hemoglobin via a urethane (carbamate) linkage.
    Type: Grant
    Filed: May 22, 1992
    Date of Patent: January 31, 1995
    Assignee: Enzon, Inc.
    Inventors: Kwang Nho, Shmuel Zalipsky, Frank Davis
  • Patent number: 5312808
    Abstract: Hemoglobin-containing solutions containing polyalkylene oxide-conjugated hemoglobin having a molecular weight greater than about 85,000 daltons and a degree of substitution of at least five polyalkylene oxide conjugates per hemoglobin molecule are described that are not associated with hemoglobinuria in mammals. A method of simultaneously fractionating and purifying polyalkylene oxide-conjugated hemoglobins is also disclosed.
    Type: Grant
    Filed: October 13, 1992
    Date of Patent: May 17, 1994
    Assignee: Enzon, Inc.
    Inventors: Robert G. L. Shorr, Myung-Ok P. Cho, Kwang Nho
  • Patent number: 5264555
    Abstract: Methods are disclosed for separating hemoglobin from erythrocytes by contacting erythrocytes with a hypotonic buffer solution at a rate sufficient to render the release of hemoglobin from said erythrocytes without significant lysis. The hemoglobin is then separated from the erythrocytes. Methods are also disclosed for purifying hemoglobin solutions of DNA, endotoxins and phospholipids by contacting the hemoglobin solutions with an anion exchange medium.
    Type: Grant
    Filed: July 14, 1992
    Date of Patent: November 23, 1993
    Assignee: Enzon, Inc.
    Inventors: Robert G. L. Shorr, Kwang Nho, Myung-ok P. Cho, Chyi Lee, Barbara Czuba, Hariharan Shankar
  • Patent number: 5234903
    Abstract: The present invention relates to chemically modified hemoglobin produced by a novel and efficient method in which stroma-free hemoglobin is first effectively deoxygenated and reduced and then conjugated with a polyalkylene oxide such as polyethylene glycol (PEG) under conditions which maintain the structural integrity of the heme oxygen binding site. In specific, preferred embodiments of the invention, the deoxygenation and reduction is performed under an inert atmosphere by the amino acid cysteine. In additional specific, preferred embodiments, the structural integrity of the heme oxygen binding site is maintained by a high anionic concentration in the reaction mixture. In further preferred specific embodiments of the invention, the polyalkylene oxide is polyethylene glycol; in still further preferred specific embodiments of the invention, the polyalkylene oxide is linked to hemoglobin via a urethane (carbamate) linkage.
    Type: Grant
    Filed: November 20, 1990
    Date of Patent: August 10, 1993
    Assignee: Enzon, Inc.
    Inventors: Kwang Nho, Shmuel Zalipsky, Frank Davis